HRTS
Tema GLP-1 Obesity & Cardiometabolic ETF · NAS
- Category Health Care
- Expense Ratio 0.75%
- Listing Date Nov 21, 2023
- Volume 10,016.0
- Market Cap (AUM) $70.83M
Performance
-4.77%
1W
-3.0%
1M
-16.31%
3M
-8.26%
6M
-3.38%
YTD
+1.85%
1Y
Top Holdings
-
Name
Symbol%Assets
- Vertex Pharmaceuticals IncorporatedVRTX6.18%
- Eli Lilly and CompanyLLY5.71%
- Amgen Inc.AMGN5.48%
- Novo Nordisk A/S Class BNOVO.B5.25%
- DexCom, Inc.DXCM3.84%
- Cytokinetics, IncorporatedCYTK3.56%
- Insulet CorporationPODD3.30%
- Mereo BioPharma Group plc Sponsored ADRMREO3.24%
- Edwards Lifesciences CorporationEW3.16%
- BridgeBio Pharma, Inc.BBIO2.96%
Technical Analysis of HRTS 2024-12-20
Technical Scores and Rating
Moving Average Score
Oscillator Score
Technical Rating
Recent News & Updates
- 2024-04-21 23:10
10 Best Performing Biotech ETFs in 2024(Insidermonkey)
- 2024-03-13 12:40
'Continued innovation' is key when investing in weight loss trend(Yahoo Finance Video)
Page 1 of 1
previousnext
Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.